Pharvaris (PHVS) Capital Expenditures Growth (1y) (2021 - 2026)
Powered by 
Analysis
Pharvaris (PHVS) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 22,433.30% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -73.62% |
| 10 | Pharvaris | 2.15 Bn | 1.78 Bn | 85,072.10 | -266.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -266.08% |
| Mar 31, 2026 | 63.99% |
| Dec 31, 2025 | 98.96% |
| Sep 30, 2025 | -100.00% |
| Jun 30, 2025 | 100.00% |
| Mar 31, 2025 | -407.66% |
| Dec 31, 2024 | -463.14% |
| Sep 30, 2024 | 32.07% |
| Jun 30, 2024 | -29.47% |
| Mar 31, 2024 | -63.26% |
| Dec 31, 2023 | -26.61% |
| Sep 30, 2023 | 17.46% |
| Jun 30, 2023 | -11.03% |
| Mar 31, 2023 | 30.96% |
| Dec 31, 2022 | 69.24% |
| Sep 30, 2022 | 152,205,075.49% |
| Jun 30, 2022 | -187,626,927.31% |
| Mar 31, 2022 | -143.79% |
| Dec 31, 2021 | 100.00% |
| Sep 30, 2021 | -63.73% |